Dr. Roscoe M. Moore, Jr., D.V.M., Ph.D., D.Sc.
Until his retirement, Dr. Roscoe M. Moore, Jr. served with the United States Department of Health and Human Services (HHS) and was for the last twelve years of his career the principal person responsible for global development support within the Office of the Secretary, HHS, with primary emphasis on Continental Africa and other less developed countries of the world. He was the principal liaison person between the HHS and Ministries of Health in Africa with regard to the development of infrastructure and technical support for the delivery of preventive and curative health needs for the continent.
Dr. Moore received his Bachelor of Science and Doctor of Veterinary Medicine degrees from Tuskegee Institute; his Master of Public Health degree in Epidemiology from the University of Michigan; and his Doctor of Philosophy degree in Epidemiology from the Johns Hopkins University. He was awarded the Doctor of Science degree (Honoris Causa) in recognition of his distinguished public health career by Tuskegee University.
Dr. Moore was a career officer within the Commissioned Corps of the United States Public Health Service (USPHS) entering with the U.S. National Institutes of Health (NIH) and rising to the rank of Assistant United States Surgeon General (Rear Admiral, USPHS) within the Immediate Office of the Secretary, HHS. He was selected as Chief Veterinary Medical Officer, USPHS, by Surgeon General C. Everett Koop.
Dr. Moore served as an Epidemic Intelligence Service Officer with the U.S. Centers for Disease Control and Prevention (CDC). He was with the Center for Veterinary Medicine, U.S. Food and Drug Administration (FDA), before becoming Senior Epidemiologist within the National Institute for Occupational Safety and Health, CDC. He served as the Chief Epidemiologist with the Center for Devices and Radiological Health, FDA. He directed the Epidemiology and Biostatistics Program and was an Assistant Professor of Oncology within the Howard University College of Medicine Cancer Center.
Dr. Dorothy Bray, Ph.D.
Dorothy Bray, Ph.D., Former Global Director of HIV Research and Senior Clinical Program Head of HIV and Opportunistic Infections for GlaxoSmithKline, to the Company’s Scientific Advisory Board. Dr. Bray held various positions of responsibility at GlaxoSmithKline.
Dr. Bray is the President and owner of ImmunoClin as well as a member of the Scientific Staff and the Head of Scientific Business Development of The Medical Research Council Clinical Trials Unit. As well, Dr. Bray has authored or co-authored multiple publications and has an extensive network of collaborations and contacts with pharmaceutical companies, governments, and non- government organizations in key developed and developing markets; European Commission Scientific Expert.
Dr. Bray’s extensive experience in the field of HIV drug development will compliment Cannabis Sciences’ prestigious Scientific Advisory Board as the company embarks on the research and development of a phytocannabinoid based HIV TAT inhibitor. Dr. Bray has significant expertise in clinical development and market positioning for novel drugs.
Dr. Michael J. Goldblatt
Dr. Goldblatt, the Former Director of Defense Sciences at the Defense Advanced Research Projects Agency (DARPA), holds extensive experience in successfully pioneering next-generation technologies, including host-oriented therapeutics for infectious disease. He received his B.A. in Biology from Reed College and his Ph.D. and J.D. from the University of California-Davis and is admitted to practice law in New York and Washington, D.C. and with the United States Patent Bar.
Dr. Goldblatt is also the President and CEO of Functional Genetics, a privately held biotechnology Company founded in 2001 (www.functional-genetics.com). Functional Genetics focuses on the development of new antibody-based therapeutics to prevent and treat a broad spectrum of viruses including HIV, Herpes, and respiratory illnesses. Functional Genetics' leading candidate FGI-101-1A6 is a fully human monoclonal antibody which targets and eliminates cells that have been infected by various viruses including HIV-1 and influenza. FGI-101-1A6 has successfully completed its Phase IA clinical trial.
Dr. Goldblatt has over 20 years of experience working in biotechnology, product development, and regulatory affairs. He served as the Science and Technology Officer at McDonald's Corporation and Director of Scientific and Regulatory Affairs at General Foods Corporation. Dr. Goldblatt has extensive knowledge and experience in the identification and commercial development of early stage technologies.
Dr. Alan Shackelford
Dr. Alan Shackelford is a graduate of the University of Heidelberg School of Medicine in Heidelberg, Germany and completed his postgraduate medical training at major teaching hospitals of the Harvard Medical School, including a residency in internal medicine and clinical Fellowships in nutritional and behavioral medicine as well as a Harvard Medical School research fellowship.
Dr. Shackelford’s interests are wide-ranging, and include the investigation and study of the medical uses of cannabis as well as applying principles of behavioral medicine to the treatment of stress-related illnesses, obesity, insomnia and tobacco dependence.
He has advised legislators in Colorado and Connecticut on the medical uses of cannabis during deliberations on bills establishing and regulating medical use of cannabis, has testified a number of times before state senate and house committees in Colorado and Connecticut on the medical uses of marijuana and serves on the Colorado Department of Revenue Medical Marijuana Advisory Work Group and a similar group advising the City and County of Denver. Dr. Shackelford is principle physician of Amarimed of Colorado, a medical practice devoted to the study and evaluation of cannabis as a medical treatment option.
Dr. William L. Courtney
Dr. William Courtney, in addition to holding a B.S. in Microbiology and M.D. degree, has a Post Doctorate in Forensic Examination and Forensic Medicine. He is a member of the International Cannabinoid Research Society, the International Association of Cannabis as Medicine, and the Society of Clinical Cannabis. Dr. Courtney teaches Continuing Medical Education (CME) courses in clinical cannabis, and a Survey Course on Endogenous Cannabinoid System, and hosted the Second International CB2 Conference in California.
Dr J. Thomas August
Dr. August’s distinguished career in clinical research directed at the molecular biology and protein structure of RNA viruses, and clinical exploration of human immunology has positioned him as a leading authority on human immune response mechanisms.
Dr. August currently holds the positions of a University Distinguished Service Professor of Pharmacology and Molecular Sciences, and Oncology at The Johns Hopkins University School of Medicine, Professor of Medicine, National University of Singapore; and Professor, Perdana University Graduate School of Medicine, Malaysia.
Dr. August has been involved with the development of a new generation of HIV vaccines and the protein antigenic structure of leading viral pathogens, including HIV-1, influenza, and other pathogens including dengue and West Nile viruses. His numerous publications are reflective of scientific commercial enterprises in cancer and HIV.
Dr. Ritchard L. Fishman
Dr. Fishman established his practice in 1961, and since then has been seeing patients of all ages for Diabetes, Hypertension, Weight Loss, Arthritis, Pain Management and many other medical problems. Dr. Fishman is widely recognized as a leader in the research in these fields. Since 1998, Dr. Fishman has been involved in clinical trials for medications, treatments, devices and vaccines for major pharmaceutical companies seeking FDA approval. Dr. Fishman is also a Chairman of the New Life Diabetes Center’s Medical Review Board and is responsible for reviewing all medical operations supervised by this Center. Dr. Fishman graduated Ohio State University in 1953 where he earned a Bachelor of Science degree with a Major in Biology. He also received his Medical Doctor degree from Ohio State University in 1957. Dr. Fishman has professional affiliations with the Downey Community Hospital, Whittier Presbyterian Hospital, and Whittier Hospital. Also, he has been a guest lecturer with the Western University School of Osteopathic Medicine and Senior Medical advisor for New Life Diabetic Centers in California and Nevada.